Continuity of care and treatment intensity at the end of life in Swiss cancer patients.
Journal
European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
medline:
5
6
2023
pubmed:
9
4
2023
entrez:
8
4
2023
Statut:
ppublish
Résumé
Continuity of care (COC) was shown to be associated with fewer hospitalizations. We aimed to evaluate whether COC was associated with intensive intervention(s) at the end of life (IEOL), a preference-sensitive outcome, in cancer patients. The study is based on claims data of patients with incident use of anti-neoplastics in Switzerland. COC Index, Usual Provider Continuity score, Sequential Continuity index and Modified Modified Continuity Index were calculated based on consultations with the usual ambulatory care physician. Treatment intensity was evaluated in the last 6 months of life, and COC was evaluated in months 18-6 before death in those who died between 24 and 54 months after incident cancer. IEOL comprised life-sustaining interventions (cardiac catheterization, cardiac assistance device implantation, pulmonary artery wedge monitoring, cardiopulmonary resuscitation/cardiac conversion, gastrostomy, blood transfusion, dialysis, mechanical ventilator utilization and intravenous antibiotics) and measures specifically used in cancer patients (last dose of chemotherapy ≤14 days of death, a new chemotherapy regimen starting <30 days before death, ≥1 emergency visit in the last month of life, ≥1 hospital admission or spending >14 days in hospital in the last month of life and death in an acute-care hospital). All COC scores were inversely associated with the occurrence of an IEOL, as were older age, homecare nursing utilization and density of ambulatory care physicians. For COC Index, odds ratio was 0.55 (95% confidence interval 0.37-0.83). COC scores were consistently and inversely related to IEOL. The study supports efforts to improve COC for cancer patients at their end of life.
Sections du résumé
BACKGROUND
Continuity of care (COC) was shown to be associated with fewer hospitalizations. We aimed to evaluate whether COC was associated with intensive intervention(s) at the end of life (IEOL), a preference-sensitive outcome, in cancer patients.
METHODS
The study is based on claims data of patients with incident use of anti-neoplastics in Switzerland. COC Index, Usual Provider Continuity score, Sequential Continuity index and Modified Modified Continuity Index were calculated based on consultations with the usual ambulatory care physician. Treatment intensity was evaluated in the last 6 months of life, and COC was evaluated in months 18-6 before death in those who died between 24 and 54 months after incident cancer. IEOL comprised life-sustaining interventions (cardiac catheterization, cardiac assistance device implantation, pulmonary artery wedge monitoring, cardiopulmonary resuscitation/cardiac conversion, gastrostomy, blood transfusion, dialysis, mechanical ventilator utilization and intravenous antibiotics) and measures specifically used in cancer patients (last dose of chemotherapy ≤14 days of death, a new chemotherapy regimen starting <30 days before death, ≥1 emergency visit in the last month of life, ≥1 hospital admission or spending >14 days in hospital in the last month of life and death in an acute-care hospital).
RESULTS
All COC scores were inversely associated with the occurrence of an IEOL, as were older age, homecare nursing utilization and density of ambulatory care physicians. For COC Index, odds ratio was 0.55 (95% confidence interval 0.37-0.83).
CONCLUSIONS
COC scores were consistently and inversely related to IEOL. The study supports efforts to improve COC for cancer patients at their end of life.
Identifiants
pubmed: 37029913
pii: 7111253
doi: 10.1093/eurpub/ckad047
pmc: PMC10234661
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-402Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Public Health Association.
Références
Med Care. 2010 Feb;48(2):118-24
pubmed: 20057327
Health Serv Res. 2022 Aug;57(4):853-862
pubmed: 34386976
Cancer Manag Res. 2021 Oct 02;13:7569-7577
pubmed: 34629903
J Clin Oncol. 2003 Mar 15;21(6):1133-8
pubmed: 12637481
Ann Fam Med. 2015 Mar;13(2):123-9
pubmed: 25755033
Lancet. 2011 Oct 15;378(9800):1408-13
pubmed: 21982520
Palliat Med. 2014 Dec;28(10):1167-96
pubmed: 24866758
J Health Serv Res Policy. 2006 Oct;11(4):196-201
pubmed: 17018192
Cancer. 2016 May 1;122(9):1453-60
pubmed: 27018875
J Palliat Med. 2003 Dec;6(6):911-8
pubmed: 14733683
Palliat Med. 2014 Feb;28(2):176-83
pubmed: 23779252
Isr J Health Policy Res. 2012 May 23;1(1):21
pubmed: 22913949
J Clin Oncol. 2004 Jan 15;22(2):315-21
pubmed: 14722041
Lancet. 2017 Jul 8;390(10090):156-168
pubmed: 28077234
Psychooncology. 2007 Sep;16(9):863-8
pubmed: 17245696
Eur J Public Health. 2017 Oct 1;27(5):814-821
pubmed: 28957486
PLoS One. 2015 Apr 14;10(4):e0123764
pubmed: 25875471
JAMA Health Forum. 2022 Jan 4;3(1):e214464
pubmed: 36218864
Palliat Med. 2019 Jul;33(7):783-792
pubmed: 31068119
Cancer. 2012 May 15;118(10):2571-82
pubmed: 22045610
Eur J Public Health. 2017 Feb 1;27(1):25-30
pubmed: 28177477
Sci Rep. 2020 Nov 12;10(1):19716
pubmed: 33184374
JAMA. 2017 Oct 17;318(15):1479-1488
pubmed: 28973088
BMJ. 2017 Feb 1;356:j84
pubmed: 28148478
J Clin Oncol. 2006 Nov 10;24(32):5112-6
pubmed: 17093272
Arch Intern Med. 2010 Oct 11;170(18):1671-7
pubmed: 20937927
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
BMC Public Health. 2013 Oct 30;13:1030
pubmed: 24172142
JAMA. 2016 Jan 19;315(3):284-92
pubmed: 26784776
Lancet. 2017 Jul 8;390(10090):169-177
pubmed: 28077232
Arch Intern Med. 2009 Jan 12;169(1):81-6
pubmed: 19139328
ESMO Open. 2021 Aug;6(4):100225
pubmed: 34474810
Patient Prefer Adherence. 2020 Nov 18;14:2253-2262
pubmed: 33239869
Arch Intern Med. 2009 Mar 9;169(5):493-501
pubmed: 19273780
Ann Intern Med. 2004 Oct 5;141(7):533-6
pubmed: 15466770
Ann Oncol. 2009 Feb;20(2):343-8
pubmed: 18765460
Curr Oncol. 2015 Oct;22(5):341-55
pubmed: 26628867
Cancer Manag Res. 2018 Mar 15;10:481-491
pubmed: 29588617